8-K - MBOT - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d)

of

the Securities Exchange Act of 1934

Dateof Report (Date of earliest event reported): November 9, 2023

MICROBOT

MEDICAL INC.

(Exactname of registrant as specified in its charter)

Delaware	000-19871	94-3078125
(State or other jurisdiction<br><br> <br>of incorporation)	(Commission File Number)	(IRS Employer<br><br> <br>Identification No.)

288Grove Street, Suite 388

Braintree,MA 02184

(Addressof Principal Executive Offices) (Zip Code)

Registrant’stelephone number, including area code: (781) 875-3605

(FormerName or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications<br> pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant<br> to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications<br> pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications<br> pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par<br> value	MBOT	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On November 9, 2023, the Board of Directors of Microbot Medical Inc. (the “Company”) authorized the reinstatement in full of the annual compensation and social and fringe benefits of each of Rachel Vaknin, the Company’s Chief Financial Officer, and Simon Sharon, the Company’s Chief Technology Officer and General Manager, effective retroactive to November 1, 2023. Such compensation and benefits were reduced in May 2023 as a result of the Company’s cost reduction plan.

Mr. Harel Gadot, the Company’s CEO, is continuing to be subject to his 50% reduction as part of the May 2023 cost reduction plan.

Item9.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.	Description
104	Cover Page Interactive Data File (formatted as Inline<br> XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	/s/ Harel Gadot
	Harel Gadot
	Chairman, President and Chief Executive Officer
Date: November 14, 2023